Mini Review - Journal of Clinical Ophthalmology (2021) Volume 5, Issue 0
Reduced fluence corneal cross-linking in mild to moderate keratoconus: A review.
Keratoconus progression, especially at younger ages, is aggressive and may not stop on its own. The idea of improving biomechanical strength of the cornea to prevent disease progression and decrease its optical consequences and possibly need to corneal transplantation was a dream which almost came true. Since then, CXL has been approved by Food and Drug Administration and become a robust treatment option for progressive keratoconus as well as other conditions including post-LASIK ectasia. The chemical interaction of UVA and riboflavin is the basic principle of CXL which increases interfibrillar covalent bonds through photo polymerization of riboflavin and activation of oxidative pathwaysAuthor(s): Fateme Alipour, Parya Abdolalizadeh